Accuray’s CyberKnife S7 System is capable of treating cancerous and benign tumours and neurologic disorders. Credit: Accuray Incorporated.

Accuray has launched the CyberKnife S7 System for all stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments.

This robotic, non-invasive radiation therapy device is capable of treating cancerous and benign tumours throughout the body, and neurologic disorders.

It uses Synchrony motion synchronisation technology that uses artificial intelligence (AI) to adapt radiation delivery in real time to the movement of the patient and tumour throughout the course of treatment.

Movements such as breaths, or coughs, muscles tensing and relaxing, and fluids and gasses displacing internal organs may occur during the treatment and that can impact the location of the tumour target when the radiation beam is delivered.

The robotic design of the system allows the delivery of radiation from a range of unique angles, expanding the possible positions from which radiation beams can be delivered.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It will enable the physician to maximise radiation dose delivered to the tumour and to reduce the dose to surrounding healthy tissues.

Accuray president and CEO Joshua Levine said: “The CyberKnife system has continued to evolve since the first patient was treated more than 25 years ago and it remains the ‘go-to’ device for clinicians who want to confidently deliver precise and accurate stereotactic treatments on a day-in, day-out basis.

“With the introduction of the CyberKnife S7 System, Accuray is continuing its legacy of innovation. We believe this new system will make it easier for Geisinger clinicians to successfully deliver SRS and SBRT and achieve their patient-first treatment objectives, a priority for their team and ours.”